FDA Approves New Companion Diagnostics for Prostate Cancer Treatment
The tissue- and blood-based tests identify patients with specific gene mutations who may benefit from a combination therapy.
Read More
Search Results for: prostate cancer
Roche to Acquire PathAI to Expand Digital Pathology and AI Diagnostics
The $750 million deal aims to integrate AI-powered technology and image management systems into pathology laboratory workflows.
Read More
ctDNA Blood Test May Help Guide Treatment Selection for Spreading Cancer
Research presented at ESTRO 2026 suggests circulating tumor DNA can identify which patients will benefit from combined radiation and drug therapy.
Read More
Tempus Launches AI-Powered Prostate Cancer Test for Metastatic Patients
Tempus has launched the ArteraAI Prostate Test, a CLIA-certified, CAP-accredited AI tool for metastatic hormone-sensitive prostate cancer, offering personalized risk estimates and designed to support treatment decisions, according to the company.
Read More
Cleveland Diagnostics Receives ISO Certification, Advancing Expansion for Prostate Cancer Test
Cleveland Diagnostics has received ISO 13485:2016 certification for its IsoPSA Assay, supporting scaled U.S. commercialization following recent FDA approval for prostate cancer risk assessment.
Read More